The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study

References

• Howlader N, Noone A, Krapcho M, et al. SEER cancer statistics review, 1975–2013. Bethesda (MD): National Cancer Institute. 2016. p. 19.
   Google Scholar
• Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23(1):1–34.
   PubMed Web of Science ®Google Scholar
• Sobrero AF, Puccini A, Shi Q, et al. A new prognostic and predictive tool to enhance shared decision making in stage III colon cancer. Am Soc Clin Oncol. 2020;138:182–188.
   Google Scholar
• André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27(19):3109–3116.
   PubMed Web of Science ®Google Scholar
• André T, De Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in stage II to III colon cancer: updated 10-year survival and outcomes according to BRAF mutation and mismatch repair status of the MOSAIC study. J Clin Oncol. 2015;33(35):4176–4187.
   PubMed Web of Science ®Google Scholar
• Erlichman C, O'Connell M, Kahn M, et al. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol. 1999;17(5):1356–1363.
   PubMed Web of Science ®Google Scholar
• Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the cancer care Ontario program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol. 2004;22(16):3395–3407.
   PubMed Web of Science ®Google Scholar
• Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–1806.
   PubMed Web of Science ®Google Scholar
• Group QC. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–2029.
   PubMed Web of Science ®Google Scholar
• Yothers G, O'Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for Colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–3774.
   PubMed Web of Science ®Google Scholar
• Argiles G, Tabernero J, Labianca R, et al. Localised colon cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(10):1291–1305.
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook AP, Al-Hawary MM, Arain MA, et al. Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(3):329–359.
   PubMed Web of Science ®Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99.
   PubMed Web of Science ®Google Scholar
• Gunderson LL, Jessup JM, Sargent DJ, et al. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010;28(2):264–271.
   PubMed Web of Science ®Google Scholar
• O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. J Natl Cancer Inst. 2004;96(19):1420–1425.
   PubMed Web of Science ®Google Scholar
• Kim MJ, Jeong S-Y, Choi S-J, et al. Survival paradox between stage IIB/C (T4N0) and stage IIIA (T1-2N1) colon cancer. Ann Surg Oncol. 2015;22(2):505–512.
   PubMed Web of Science ®Google Scholar
• Tejpar S, Stintzing S, Ciardiello F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials. JAMA Oncol. 2017;3(2):194–201.
   PubMed Web of Science ®Google Scholar
• Ishihara S, Murono K, Sasaki K, et al. Impact of primary tumor location on postoperative recurrence and subsequent prognosis in nonmetastatic colon cancers: a multicenter retrospective study using a propensity score analysis. Ann Surg. 2018;267(5):917–921.
   PubMed Web of Science ®Google Scholar
• Casadaban L, Rauscher G, Aklilu M, et al. Adjuvant chemotherapy is associated with improved survival in patients with stage II colon cancer. Cancer. 2016;122(21):3277–3287.
   PubMed Web of Science ®Google Scholar
• Verhoeff S, Van Erning F, Lemmens V, et al. Adjuvant chemotherapy is not associated with improved survival for all high‐risk factors in stage II colon cancer. Int J Cancer. 2016;139(1):187–193.
   PubMed Web of Science ®Google Scholar
• Mukkamalla SKR, Huynh DV, Somasundar PS, et al. Adjuvant chemotherapy and tumor sidedness in stage II colon cancer: analysis of the national cancer data base. Front Oncol. 2020;10:1793.
   Web of Science ®Google Scholar
• Liu F, Li C, Jia H, et al. Is there a prognostic value of tumor location among Chinese patients with colorectal cancer? Oncotarget. 2017;8(24):38682–38692.
   PubMedGoogle Scholar
• Weiss JM, Pfau PR, O'Connor ES, et al. Mortality by stage for right-versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results–medicare data. J Clin Oncol. 2011;29(33):4401–4409.
   PubMed Web of Science ®Google Scholar
• Skancke M, Arnott SM, Amdur RL, et al. Lymphovascular invasion and perineural invasion negatively impact overall survival for stage II adenocarcinoma of the colon. Dis Colon Rectum. 2019;62(2):181–188.
   PubMed Web of Science ®Google Scholar
• Rebuzzi SE, Pesola G, Martelli V, et al. Adjuvant chemotherapy for stage II colon cancer. Cancers. 2020;12(9):2584.
   PubMed Web of Science ®Google Scholar
• Swanson RS, Compton CC, Stewart AK, et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003;10(1):65–71.
   PubMed Web of Science ®Google Scholar
• Le Voyer T, Sigurdson E, Hanlon A, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003;21(15):2912–2919.
   PubMed Web of Science ®Google Scholar
• Iveson T, Sobrero AF, Yoshino T, et al. Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC). Journal of Clinical Oncology 2019;37:3501-3501.
   Google Scholar